CO-ADMINISTRATION OF WARFARIN AND ETHYL EICOSAPENTAENOATE

摘要

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on warfarin therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

主权项

1. A pharmaceutical composition comprising warfarin, the composition providing a similar at least one pharmacokinetic endpoint of warfarin and/or at least one anticoagulation pharmacodynamic endpoint of warfarin, when co-administered with ethyl eicosapentaenoate, compared to a second pharmaceutical composition comprising warfarin administered without the ethyl eicosapentaenoate.